Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00391196 · ClinicalTrials.gov registry record · Phase 3
A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 975
- Enrollment target
NCT00391196: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00391196 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 975 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00391196, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 975 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.
Interventions
- DRUG Placebo
- DRUG CP-945,598
- DRUG CP-945,598 Treatment B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
Why NCT00391196 stopped before completion
NCT00391196 is an interventional study that assigns participants to a tested intervention. The registered 975 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00391196 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00391196 about?
NCT00391196 is a clinical study titled "A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients". The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.
What is the current status of trial NCT00391196?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 975 participants. The study started on 2006-11. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00391196?
The interventions under investigation include: Placebo (DRUG), CP-945,598 (DRUG), CP-945,598 Treatment B (DRUG).
Who is sponsoring clinical trial NCT00391196?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00391196's enrollment target sits among peer trials
975 325th of 2000 higher than 1,673 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- NCT06820736 · 975 participants · NA
A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion
- NCT07216482 · 975 participants · Phase 3
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia